Limits...
Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin.

Chater PI, Wilcox MD, Brownlee IA, Pearson JP - Carbohydr Polym (2015)

Bottom Line: Alginates were shown to reduce pepsin activity by up to 53.9% (±9.5SD) in vitro.Limited inhibition of trypsin was shown.Significant inhibition of proteolysis was shown in the gastric phase of digestion, but not the small intestinal phase.

View Article: PubMed Central - PubMed

Affiliation: Institute for Cell and Molecular Biosciences (ICaMB), Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom. Electronic address: peter.chater@ncl.ac.uk.

No MeSH data available.


Related in: MedlinePlus

Bovine serum albumin digestion in gastric phase of a model gut system with and without SF120 alginate. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of SF120. Control digestion is represented as as (■) and digestion with FMC3 at 125 mg as (▴), 250 mg (▾) and 500 mg (♦). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of SF120 alginate significantly inhibited the gastric digestion of protein by 32.9% (P = 0.0025), 30.8% (P = 0.007) and 50.5% (P = 0.001), respectively (t-test).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4539341&req=5

fig0035: Bovine serum albumin digestion in gastric phase of a model gut system with and without SF120 alginate. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of SF120. Control digestion is represented as as (■) and digestion with FMC3 at 125 mg as (▴), 250 mg (▾) and 500 mg (♦). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of SF120 alginate significantly inhibited the gastric digestion of protein by 32.9% (P = 0.0025), 30.8% (P = 0.007) and 50.5% (P = 0.001), respectively (t-test).

Mentions: With SF120 at T[15], the highest levels of inhibition were achieved with the highest concentration of 500 mg SF120 (Fig. 7). At T[30], protein digestion was reduced by 35.4% (P = 0.010), 47.3% (P = 0.033) and 62.1% (P = 0.002) as compared to control with 125, 250 and 500 mg of SF120 alginate, respectively. At T[45], protein digestion was reduced by 60.8% (P = 0.003), 37.5% (P = 0.003) and 70.2% (P = 0.019) with 125, 250 and 500 mg of SF120 alginate respectively. By the final timepoint at T[60], protein digestion was reduced by 32.9% (P = 0.0025), 30.8% (P = 0.007) and 50.5% (P = 0.001) with 125, 250 and 500 mg of SF120 alginate, respectively.


Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin.

Chater PI, Wilcox MD, Brownlee IA, Pearson JP - Carbohydr Polym (2015)

Bovine serum albumin digestion in gastric phase of a model gut system with and without SF120 alginate. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of SF120. Control digestion is represented as as (■) and digestion with FMC3 at 125 mg as (▴), 250 mg (▾) and 500 mg (♦). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of SF120 alginate significantly inhibited the gastric digestion of protein by 32.9% (P = 0.0025), 30.8% (P = 0.007) and 50.5% (P = 0.001), respectively (t-test).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4539341&req=5

fig0035: Bovine serum albumin digestion in gastric phase of a model gut system with and without SF120 alginate. The graph shows total protein recovered from model gut system after TCA (trichloroacetic acid) precipitation to stop enzyme activity and remove undigested polypeptides. 0.5 g BSA was digested alone (control digestion) and in the presence of varying concentrations of SF120. Control digestion is represented as as (■) and digestion with FMC3 at 125 mg as (▴), 250 mg (▾) and 500 mg (♦). All samples were tested in triplicate, errors are shown as standard deviation. At T[60] by the end of the gastric phase, 125, 250 and 500 mg of SF120 alginate significantly inhibited the gastric digestion of protein by 32.9% (P = 0.0025), 30.8% (P = 0.007) and 50.5% (P = 0.001), respectively (t-test).
Mentions: With SF120 at T[15], the highest levels of inhibition were achieved with the highest concentration of 500 mg SF120 (Fig. 7). At T[30], protein digestion was reduced by 35.4% (P = 0.010), 47.3% (P = 0.033) and 62.1% (P = 0.002) as compared to control with 125, 250 and 500 mg of SF120 alginate, respectively. At T[45], protein digestion was reduced by 60.8% (P = 0.003), 37.5% (P = 0.003) and 70.2% (P = 0.019) with 125, 250 and 500 mg of SF120 alginate respectively. By the final timepoint at T[60], protein digestion was reduced by 32.9% (P = 0.0025), 30.8% (P = 0.007) and 50.5% (P = 0.001) with 125, 250 and 500 mg of SF120 alginate, respectively.

Bottom Line: Alginates were shown to reduce pepsin activity by up to 53.9% (±9.5SD) in vitro.Limited inhibition of trypsin was shown.Significant inhibition of proteolysis was shown in the gastric phase of digestion, but not the small intestinal phase.

View Article: PubMed Central - PubMed

Affiliation: Institute for Cell and Molecular Biosciences (ICaMB), Medical School, Newcastle University, Catherine Cookson Building, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom. Electronic address: peter.chater@ncl.ac.uk.

No MeSH data available.


Related in: MedlinePlus